CClinicalTrials.gg
CompletedNCT03786913Updated Feb 8, 2019

Quantitative Muscle Ultrasound as a Marker of Progression in Children With Muscular Diseases

An observational study in Inflammatory Myopathy and Duchenne Muscular Dystrophy, sponsored by Benha University. Completed at 1 site in Egypt. Open to participants aged 2 Years to 16 Years. Per ClinicalTrials.gov, last updated 2019-02-08.

Sponsored by Benha University · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
48
Ages
2 Years to 16 Years
Sex
All
01

Study summary

The aim of our study is to Assess skeletal muscle structural status in children with inflammatory myositis and Duchenne muscular dystrophy using musculoskeletal ultrasound and to perform a longitudinal follow up of these changes over 2 years and to assess the relation between these findings with clinical parameters, functional scales, biochemical and electromyographic tests.

Read the detailed description

This study will be carried out on two groups:

  • Group (I): fifty children diagnosed to have duchenne muscular dystrophy and inflammatory myositis.

Group (II): including 20 healthy children matching age and sex as control group.

patients will be subjected to

(A) Clinical evaluation

  1. Complete history taking.
  2. Thorough clinical examination.
  3. Body mass index (BMI) assessment.
  4. Quantitative muscle strength tests
  5. Functional grading
  6. Childhood Myositis Assessment Scale. 7 (B) Laboratory assessment:

All patients will be subjected to the following measurements:

  1. Serum creatine kinase levels (CK).
  2. Serum Lactate dehydrogenase levels
  3. Serum of Liver enzymes (SGOT\& SGPT) levels.

(C) Electromyographic (EMG) assessment:

(D) Musculoskeletal ultrasound assessment (E) Statistical analysis

02

Conditions studied

  • Inflammatory Myopathy
  • Duchenne Muscular Dystrophy

Keywords

  • Inflammatory myositis
  • Duchenne Muscular Dystrophy
  • Musculoskeletal ultrasound
03

In context

Muscular Dystrophies

548 studies on the registry are indexed under Muscular Dystrophies; 89 are open to participants now.

This study's enrollment of 48 is below the median of 69 across 179 observational studies indexed under Muscular Dystrophies.

Browse Muscular Dystrophies studies →

Lead sponsor

Benha University is the lead sponsor of 356 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 16 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

the study will be performed on 2 groups Group (I): fifty children diagnosed to have inflammatory myositis and Duchenne muscular dystrophy Group (II): including 20 healthy children matching age and sex as control group.

Inclusion criteria

  • children with Duchenne muscular dystrophy (DMD). Diagnosis with DMD was established according to DMD diagnostic criteria (Jennekens et al., 1991).
  • children with juvenile dermatomyositis (JDM) according to Bohan and Peter diagnostic criteria ( (Bohan and Peter, 1975).

Exclusion criteria

Exclusion Criteria:

  • Patients with age less than 2 years were excluded from the study due to inability to perform manual muscle testing and functional scales.
  • If no final diagnosis could be established.
  • The presence of a concomitant illness that may result in peripheral neuropathy or myopathy.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
48 participants (actual)
Patient registry
No

Groups and cohorts

  • children with muscle disease

    fifty children diagnosed to have inflammatory myositis or Duchenne muscular dystrophy in whom Quantitative muscle ultrasound measurements will be performed .The captured images will be analyzed for echo intensity by means of computer-assisted grayscale histogram analysis at baseline and after 24 months.

    Diagnostic Test: Quantitative muscle ultrasound measurements

  • control group

    20 healthy children matching age and sex as control group in whom Quantitative muscle ultrasound measurement will be performed at baseline

    Diagnostic Test: Quantitative muscle ultrasound measurements

Interventions

  • Diagnostic testQuantitative muscle ultrasound measurements

    Quantitative ultrasound measurements will be performed to biceps, forearm flexors, quadriceps and tibialis anterior according to a standard protocol; for each muscle three consecutive measurements will be made to minimize variation in echo intensity during analysis .The captured images will be analyzed offline for echo intensity by means of computer-assisted grayscale histogram analysis.

06

What researchers measure

Primary outcomes

  1. Kendall's manual muscle testing

    Kendall's 0 -10 point scale measures strength of each muscle group score 0 is the weakest (worst) and 10 is the strongest (best). The following muscles were tested bilaterally: the biceps brachii muscle (BB), the forearm flexors (FF), the rectus femoris muscle (RF), the tibialis anterior muscle (TA)

    Time frame: 24 months

  2. Childhood myositis assessment scale

    used to assess the severity of muscle involvement in children with dermatomyositis. The scores for the 14 items are summated to give a total score ranging from 0 (worst) to 52 (best)

    Time frame: 24 months

  3. Serum creatine kinase (CK) levels

    CK measured in U/L using ELISA

    Time frame: 24 months

  4. Serum Lactate dehydrogenase (LDH) levels

    CK measured in IU/L using ELISA

    Time frame: 24 months

  5. Aspartate aminotransferase (AST)

    AST measured in U/L using ELISA

    Time frame: 24 MONTHS

  6. alanine aminotransferase (ALT)

    ALT measured in U/L using ELISA

    Time frame: 24 months

  7. motor unit potential (MUP) duration

    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the MUP duration measured in milliseconds.

    Time frame: 24 months

  8. motor unit peak-to-peak amplitude

    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the peak-to-peak amplitude measured in microvolt

    Time frame: 24 months

  9. motor unit area to amplitude ratio (AAR)

    quantitative electromyography (QEMG) in the most affected rectus femoris and biceps brachii muscles will be performed and The motor unit potentials will be reviewed offline for the needle-detected EMG signals will be analyzed by the device software for the motor unit AAR .

    Time frame: 24 months

07

Study locations

1 site
  • Benha University Hospital
    Banhā, Qalubiya 13518, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 8, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03786913
Lead sponsor
Benha University
Responsible party
Waleed Ahmed Salaheldeen Hassan (Assistant professor, Benha University) — Principal investigator
First posted
Dec 26, 2018
Start date
Mar 8, 2016
Primary completion
Feb 2, 2019
Completion
Feb 2, 2019
Last update
Feb 8, 2019

Study contacts

Waleed Hassan, MD
principal investigator · Benha university- Qaluibya- Egypt

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion